TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cann Group ( (AU:CAN) ) has issued an update.
Cann Group Limited has announced the quotation of 567,225,103 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s capital structure and provide additional resources to support its operations and strategic initiatives, potentially strengthening its position in the medicinal cannabis market.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited operates in the pharmaceutical industry, focusing on the cultivation and production of medicinal cannabis products. The company is primarily involved in the development and commercialization of cannabis-based therapies and products, aiming to address various medical needs and conditions.
YTD Price Performance: -71.79%
Average Trading Volume: 4,115,458
Technical Sentiment Signal: Sell
Current Market Cap: A$8.66M
For a thorough assessment of CAN stock, go to TipRanks’ Stock Analysis page.